Uplyso, marketed in the US as Elelyso, is a long-term plant-cell based enzyme replacement therapy for adults with Type I Gaucher disease.
Protalix Biotherapeutics Inc. (AMEX:PLX; TASE: PLX) has obtained approval of its treatment for Gaucher's disease, Uplyso, from the Mexican Federal Commission for the Protection against Sanitary Risk and the Public Health Institute of Chile. Pfizer Inc. (NYSE: PFE; LSE: PFZ) will sell Uplyso in both countries.
Uplyso, marketed in the US as Elelyso, is a long-term plant-cell based enzyme replacement therapy for adults with Type I Gaucher disease. The company's ProCellEx proprietary plant cell-based protein manufacturing system uses genetically engineered carrot cells to produce Uplyso.
Protalix VP medical affairs Dr. Raul Chertkoff said, "Including Mexico and Chile, Uplyso has been reviewed and approved by six different regulatory authorities across the globe. Through our joint efforts with Pfizer, we are working on expanding the commercial potential for Uplyso in additional countries."
Published by Globes [online], Israel business news - www.globes-online.com - on April 29, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013